The American College of Chest Physicians (CHEST) has released a new clinical framework for lung nodule programs that integrates validated biomarker testing, including Biodesix's Nodify Lung® tests, as a key tool for risk stratification. Developed by a multidisciplinary panel of experts, the framework outlines six steps to build comprehensive lung nodule programs aiming to standardize care, reduce delays, and improve early lung cancer detection. This advancement supports clinicians in making more confident, evidence-based decisions and could lead to better patient outcomes. The framework was unveiled at the 2026 CHEST Annual Meeting and is available for download to guide healthcare organizations in optimizing lung nodule management.
The American College of Chest Physicians' new framework for lung nodule programs provides context for healthcare advancements. For readers following the health sector, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: out of 150 priced US health stocks, 87 rose and 62 fell. Notable movers include MESO at USD 11.96 with a -9.98% change and a typical hold time of 16 days, BNGO at USD 1.25 down 8.76%, and IBRX at USD 8.46 down 7.84% with a Pluang order activity of 33% Sell and 67% Buy and a typical hold time of 2 days.
The Canadian Investment Regulatory Organization (CIRO) has temporarily halted trading of all shares of Bighorn Metals Corp. (symbol HRNY) as of 1:10 PM ET on October 19, 2026. The halt is pending further information from the company and aims to maint...
The HCA Healthcare Foundation awarded $25,000 to Waypoint (formerly Virginia Home for Boys and Girls) to expand its network of adults trained to support youth mental wellness across Virginia. This funding supports Waypoint's Therapeutic Resources tea...
Angle Advisors has appointed Chris Gessner as a Managing Director, bringing over 20 years of experience in corporate finance, including lending, private equity, and M&A advisory. Gessner's background spans various transaction types and industries suc...
The FDA has approved Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. This approval is based on the AZUR-1 trial showing 68% of patients achieved complete clinical response ...
Ethereum-based crypto Pepeto is in its final presale stages ahead of a Binance listing, with rapid investor interest driving record presale speed. Pepeto addresses issues Cardano aimed to fix, such as high fees and network congestion, offering zero-f...
